ClinicalTrials.gg
RecruitingNCT05017649RASCASUpdated Jul 27, 2023

Role of A2A Receptor in Hypercholesterolemic Patients

An interventional study of Blood sample in Hypercholesterolemia, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-27.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Hypercholesterolemia with a site in France — 5 open to participants now, 11 under way, 5 of them phase 3. Hypercholesterolemia · France.

Planned enrollment
36th of 62
150 · median 300
Started
2021
with 3 others
No phase
16 of 66
4 open now
Primary completion
2026-03
later than 1 of 10 live
Registered
50th of 66
by date

Among the 66 studies in Hypercholesterolemia with a site in France, this one is the 36th largest by planned enrollment of the 62 interventional ones that give a count, is one of 4 that started in 2021, is one of 16 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 50th registered.

Hypercholesterolemia

1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

5 of the 66 studies in Hypercholesterolemia with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 58 Hypercholesterolemia studies recruiting now, 25 (43%) set no upper age limit and 21 (36%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Hypercholesterolemia with a site in France, or all of them as a file.
02

Study summary

Hypercholesterolemia promotes chronic inflammation, endothelial dysfunction, atherosclerosis and is a major risk factor for cardiovascular disease (CVD). Treatment with lipid-lowering drugs (statins, ezetimibe, PCSK9 inhibitors or LDL-apheresis) reduces the risk of major cardiovascular events in proportion to the absolute reduction of LDL-cholesterol (LDL-C). Nevertheless, a better understanding of the effects of hypercholesterolemia on the cardiovascular and immune systems could help identify all the mechanisms responsible for the excess risk of CVD in hypercholesterolemic patients and develop better prevention and treatment strategies.

Adenosine via A2A receptors (A2AR) plays a crucial role in the regulation of the cardiovascular and immune systems.

In this project, the investigators wish :

  • To study whether the expression and function of A2AR in PBMCs are altered in human hypercholesterolemia, using as a study model a larger cohort of patients with hypercholesterolemia of increasing level and severity: polygenic form, heterozygous genetic form and homozygous genetic form in comparison with healthy subjects with normal cholesterol levels.
  • To study whether A2AR expression and function in PBMCs are associated with blood levels of LDL-C and homocysteine and with the inflammatory status of patients.
  • To assess whether the cholesterol-lowering therapies currently used to reduce LDL-C levels and thus the risk of CVD in hypercholesterolemic patients have an impact on possible alterations of A2AR expression and function in PBMCs.
03

Conditions studied

  • Hypercholesterolemia

Keywords

  • hypercholesterolemia
  • adenosine receptor
  • PBMC
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged 18-80 years
  • For the group of hypercholesterolemic patients :

    • LDL-cholesterol level >1.9 g/L with or without treatment to make the diagnosis of hypercholesterolemia (laboratory test less than 12 months old at inclusion)
  • For the healthy group :

    ● No cholesterol-modifying therapy.

  • Subject not having hypercholesterolemia (biological assessment less than 12 months old at inclusion with LDL-cholesterol level \< 1.9 g/L) and not taking cholesterol-lowering treatment.
  • Subjects who are affiliated or beneficiaries of a social security plan
  • Subject agreeing to participate in the study and having signed an

Exclusion criteria

Exclusion Criteria:

  • Protected person, as defined by articles L1121-5, L1121-6 and L1121-8 of the Public Health Code: pregnant or breastfeeding woman, person deprived of liberty by judicial decision, adult person unable to give consent.
  • Person who does not understand the French language
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Other
    Healthy volunteers

    volunteers showing no hypercholesterolemia

    Biological: Blood sample

  • Experimental
    Patients with untreated hypercholesterolemia at the time of inclusion

    patients presenting hypercholesterolemia with no treatment at the time of inclusion

    Biological: Blood sample

  • Experimental
    Patients with treated hypercholesterolemia at the time of inclusion

    patients presenting hypercholesterolemia and treated at the time of inclusion

    Biological: Blood sample

Interventions

  • BiologicalBlood sample

    Blood sampling.

06

What researchers measure

Primary outcomes

  1. Quantification of A2AR expression in PBMCs

    Comparison between hypercholesterolemic patients and healthy volunteers

    Time frame: Baseline

  2. Quantification of A2AR expression in PBMCs

    Comparison between hypercholesterolemic patients and healthy volunteers

    Time frame: 3 months after initiation of treatment

  3. Quantification of A2AR function in PBMC

    Comparison between hypercholesterolemic patients and healthy volunteers

    Time frame: 3 months after initiation of treatment

  4. Quantification of A2AR function in PBMC

    Comparison between hypercholesterolemic patients and healthy volunteers

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Service Endocrinologie
    Marseille, 13005, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Mar 2026, 53 months after the start.

Of 135 non-industry interventional studies with no phase under Hypercholesterolemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's planned 53 months is above that.

Counting every sponsor, half of 153 studies reached it within 15 months; a quarter within 6 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2021
First posted
Aug 24, 2021
StartActual
Sep 20, 2021
Primary completionEst.
Mar 19, 2026
CompletionEst.
Jun 19, 2026
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05017649
Responsible party
Sponsor
First posted
Aug 24, 2021
Start date
Sep 20, 2021
Primary completion
Mar 19, 2026 (estimated)
Completion
Jun 19, 2026 (estimated)
Last update
Jul 27, 2023

Study contacts

René Valero
Contact
rene.valero@ap-hm.fr
0491387577 ext. 33
René Valéro
Contact
rene.valero@ap-hm.fr
0491387577 ext. 33
François CREMIEUX
study director · AP-HM

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion